The Expression of Chromogranin a in Dilated Cardiomyopathy and Its Relationship With Myocardial Fibrosis

Chen, R; Yu, Yoko; Zou, Yong Guang; Wang, C; Ge, Jun; Yang, Ya Ling

doi:10.1097/01.tp.0000332397.06578.93

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ventricular tachyarrhythmia and high-grade atrioventricular block are the main causes of sudden death in patients with DCM (35). With the improvement of standardized treatment for HF, the occurrence of various malignant arrhythmias may have a more important impact on the prognosis of patients with DCM than HF (36).…”

Section: Discussionmentioning

confidence: 99%

The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis

Yang,

Lv,

Zhou

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundIvabradine improves cardiac function in patients with heart failure, but its effect on dilated cardiomyopathy (DCM) remains unclear. We performed a systematic review and meta-analysis to study the efficacy and potential mechanisms of ivabradine's effect on cardiac function and prognosis in patients with DCM.MethodsWe searched PubMed, Cochrane Library, Embase, Web of Science, and four registers through September 28, 2022. All controlled trials of ivabradine for the treatment of DCM with congestive heart failure were included. Articles were limited to English, with the full text and necessary data available. We performed random- or fixed effects meta-analyses for all included outcome measures and compared the effect sizes for outcomes in patients treated with and without ivabradine. The quality of the studies was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB2.0).FindingsFive trials with 357 participants were included. The pooled risk ratio was 0.48 [95% confidence interval (CI) (0.18, 1.25)] for all-cause mortality and 0.38 [95% CI (0.12, 1.23)] for cardiac mortality. The pooled mean difference was −15.95 [95% CI (−19.97, −11.92)] for resting heart rate, 3.96 [95% CI (0.99, 6.93)] for systolic blood pressure, 2.93 [95% CI (2.09, 3.77)] for left ventricular ejection fraction, −5.90 [95% CI (−9.36, −2.44)] for left ventricular end-systolic diameter, −3.41 [95% CI (−5.24, −1.58)] for left ventricular end-diastolic diameter, −0.81 [95% CI (−1.00, −0.62)] for left ventricular end-systolic volume, −0.67 [95% CI (−0.86, −0.48)] for left ventricular end-diastolic volume, −11.01 [95% CI (−19.66, −2.35)] for Minnesota Living with Heart Failure score, and −0.52 [95% CI (−0.73, −0.31)] for New York Heart Association class.InterpretationIvabradine reduces heart rate and ventricular volume, and improves cardiac function in patients with DCM, but showed no significant effect on the prognosis of patients.

show abstract

Section: Discussionmentioning

confidence: 99%